Closed · W81XWH-16-PCRP-CCRSA · CFDA 12.420 · Discretionary
DoD Prostate Cancer Clinical Consortium Research Site Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- October 6, 2016
- Close date
- 8
- Expected awards
The verdict
DoD Prostate Cancer Clinical Consortium Research Site Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 8 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.
- Varies
- award range
- Closed
- application status
- 8
- expected awards
- 12.420
- CFDA program
Archived opportunity record
DoD Prostate Cancer Clinical Consortium Resea… is closed (last close October 6, 2016). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed October 6, 2016
Est. Total Funding
$2,600,000
Expected Awards
8
Instrument
Grant
Description
The PCRP Clinical Consortium Award mechanism was previously offered in FY05, FY06, FY08, and FY13. Overall, 57 Clinical Consortium Award applications have been received, and 35 have been recommended for funding. This year the PCRP is offering the Clinical Consortium Research Site Award mechanism to support the inclusion of Clinical Research Sites to the existing Prostate Cancer Clinical Trials Consortium (PCCTC). The Clinical Consortium Research Site Award provides the support to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute Phase II or Phase II-linked Phase I (Phase I/II) prostate cancer clinical trials. These trials will include investigations of high-impact, novel therapeutic agents or approaches for the management or treatment of prostate cancer, especially as pertaining to the FY16 PCRP overarching challenges. In accordance with PCRP goals, the conduct of Phase I/II trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer is particularly encouraged. The principal goal of the Clinical Consortium Research Site Award is to combine the efforts of leading investigators to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease the impact of prostate cancer. To facilitate global investigations, Principal Investigators (PIs) from both U.S. and international institutions are encouraged to apply. Investigators with access to patients in the Military Health System are also encouraged to apply. Submissions from institutions with enhanced access to patients from disproportionately affected populations are especially encouraged. The PCCTC currently consists of 11 Clinical Research Sites and one Coordinating Center. The Coordinating Center and Clinical Research Sites are jointly responsible for proposing, selecting, and conducting Phase II and Phase I/II clinical trials focused on prostate cancer therapeutic interventions. The structure of the Consortium is described in detail below. More information about the PCCTC can be found on its website (http://pcctc.org/). The Coordinating Center, in addition to functioning as a Clinical Research Site, serves as the Consortium information and planning nexus providing administrative, operational, and data management support services to participating Clinical Research Sites to implement Consortium clinical trials in a timely manner. Responsibilities of the Coordinating Center include the clinical trial selection process, protocol coordination, regulatory coordination, study management and monitoring, data collection, management and statistics, and intellectual/material property coordination. All Clinical Research Sites recommended for funding will be required to participate in at least one PCCTC clinical trial during the first year of the period of performance. Collectively, the Coordinating Center PI and Clinical Research Site PIs constitute the Clinical Consortium Committee (CCC), which collaboratively develops and maintains a procedure for the selection of clinical trials to be implemented within the Consortium. A representative from the PCRP must be invited to meetings of the CCC as well as any other formal meetings of the Consortium. All sites funded through this award mechanism will be responsible for working collaboratively within the PCCTC to identify new clinical trials for implementation. Any site may serve as an entry point for clinical trials that originate from outside the Consortium. The Coordinating Center is responsible for facilitating this entire process. The purpose of the PCRP Clinical Consortium Research Site Award is to provide the funding to establish the necessary collaborations and resources to rapidly execute clinical trials by the PCCTC, but will not fund research or the development of clinical protocols. As such, investigators are strongly encouraged to leverage DoD investments whenever possible by implementing DoD-funded trials.
Catch-all / unrestricted eligibility mark · W81XWH-16-PCRP-CCRSA
Grants.gov marks DoD Prostate Cancer Clinical Consortium Resea… with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).
- Code 99
- Unrestricted / see official listing
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk 301-682-5507
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
What to do next
DoD Prostate Cancer Clinical Consortium Resea… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- Compare award ranges across federal categories before you pick a single CFDA. All categories
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |